Boma Medical

Guangdong Boma Medical Technology Co., Ltd. was founded in 2012 in Songshan Lake, Dongguan. With over 1,000 employees, it is a world-renowned high-performance medical device enterprise. The company focuses on the R&D, production, and global sales of high-performance vascular interventional medical devices and therapeutic technologies, and has rapidly grown into the largest enterprise in China for the R&D, production, and sales of vascular interventional balloon catheters.

In terms of product system construction, the company has established a comprehensive product matrix covering multiple therapeutic scenarios, with more than 50 product series. The application fields include key areas such as coronary intervention, peripheral intervention, neuro intervention, hemodialysis access, and interventional accessories. Specifically, it includes core product lines such as various universal balloon catheters, functional balloon catheters, drug balloon catheters, interventional guidewires and catheters, multiple thrombectomy devices, calcification treatment devices, and energy therapy devices, fully meeting the diverse clinical needs for interventional treatment of complex vascular diseases. Among them, several products with global first or unique innovative technologies have been launched, including the coronary high-pressure cutting balloon catheter (RevoEdgeTM ArmorTM), the drug-coated peripheral balloon catheter with drug protection device for "instant high-dose drug delivery" (VasecureTM ArchaeopteryxTM), the high-pressure CTO balloon catheter (AlveoTM), the high-pressure non-compliant scoring balloon catheter (WedgeTM NC), the peripheral vascular scoring balloon catheter (Tri-WedgeTM TriceratopsTM), the non-compliant balloon dilation catheter for proximal/distal optimization technology (POTTM), and the dual-arc pre-shaped guidewire (EagleTM YigeTM). With its original technology and clinical value, the company has become a globally leading provider of interventional treatment solutions for complex vascular diseases. Additionally, 12 products have been recognized as Guangdong Province famous and high-quality high-tech products, and over 80 authorized domestic and international invention patents have been granted, laying a solid foundation for continuous innovation.

In terms of R&D and production layout, the company values global resource integration and capacity assurance. It has established 5 R&D centers and laboratories worldwide to continuously drive core technology iteration and innovative product development; built 4 production bases to ensure large-scale, high-quality supply; and set up 3 international operation centers to provide efficient operational support and service assurance for global market expansion.

In terms of market coverage, the company's products have been successfully sold to over 100 countries and regions worldwide, serving tens of thousands of hospitals and medical centers. With stable product performance, systematic treatment solutions, and professional technical support, the company has established a strong brand image in the domestic and international vascular interventional medical device market, gradually building a globalized market layout and customer service network.

The company has long implemented the trinity business development strategy of "Innovation + Scale + Internationalization," and has grown into a transnational platform enterprise with high-speed development and significant industry influence in the global vascular intervention field. "Empowering China's original innovation, benefiting global patients" is also the core development philosophy of the company's technological innovation and global industrialization. Since its inception, the company has maintained high-intensity R&D investment, built a comprehensive and efficient R&D team and an IPD product development system. Relying on core scientific research platforms such as the Guangdong Province Vascular Interventional Treatment Technology and Device Engineering Technology Research Center, the Dongguan Key Laboratory for Vascular Interventional Medical Device R&D, and CNAS laboratories, the company has achieved multiple global breakthroughs in product technology and core processes through global industry-university-research cooperation and medical-industrial innovation collaboration.

As a medical technology innovation platform enterprise leading in innovation, technology, scale, and globalization in the field of complex vascular interventional treatment, Boma Medical has maintained long-term stable and rapid development in both domestic and international markets since achieving sales. The compound annual growth rate of operating revenue from 2022 to 2024 reached 48.98%, making it an enterprise with long-term high growth potential in the global vascular intervention industry. The company has established international operation centers in China, Europe, and the United States, and has local marketing offices in multiple countries and regions, providing efficient and professional services to global customers and partners. Currently, it has established a long-term stable marketing channel system in over 100 countries and regions worldwide, with over 200 overseas distributors and nearly 800 domestic distributors, serving tens of thousands of hospitals and medical centers.

Boma Medical has a comprehensive qualification and honor system. It is a national high-tech enterprise, a national specialized and innovative "key little giant" enterprise, and has been rated as a Guangdong Province manufacturing single champion enterprise, a Dongguan Top 100 innovative enterprise, and a Dongguan doubling enterprise. It has won the gold award of the first Guangdong-Hong Kong-Macao Greater Bay Area (Guangdong) High-Value Trademark Brand Cultivation Competition, the special prize of the first Dongguan Science and Technology Innovation and Entrepreneurship Competition, and more. In addition, the company has repeatedly ranked on industry authoritative lists, including the China Innovative Medical Device Top 100 and China Innovative Enterprises Top 150 (Qingke List).